HLB Genex Appoints Kim So-young as New Vice President to Accelerate Bio Solutions Transition

Kim So-young, new Vice President of HLB Genex
Kim So-young, new Vice President of HLB Genex [Photo=HLB Genex]

HLB Genex announced on June 16 that it has appointed Dr. Kim So-young as its new Vice President to strengthen its global healthcare business.
Kim brings over 20 years of experience in bio research and development (R&D) and commercialization from CJ CheilJedang. She began her career at CJ CheilJedang's Bio Research Institute, where she held key positions, including leading amino acid research, overseeing bio R&D, and managing the Animal Nutrition (AN) division.
Recognized for her R&D capabilities and outstanding business performance, Kim was appointed as CJ CheilJedang's first female internal director. She also contributed to achieving record quarterly operating profits in the bio sector during the second quarter of 2021 while leading the animal nutrition business.
As CJ CheilJedang secured competitiveness in the global amino acid market, including lysine and tryptophan, Kim played a crucial role as a key leader across both operational and managerial aspects.
With this appointment, HLB Genex plans to accelerate the development of high-value protein and peptide materials using synthetic biology and precision fermentation technologies, building on its existing industrial enzyme business. The company also aims to expand into medical food, personalized nutrition, and anti-aging bio solution markets.
A company representative stated, "Kim's expertise in commercialization and scaling up will play a vital role in enhancing HLB Genex's business and securing new growth engines."
The representative added, "Kim's core strength lies in her proven ability to translate R&D achievements into actual business outcomes, and we expect her to drive substantial revenue growth in high-value healthcare material markets such as medical food and anti-aging."
Meanwhile, HLB Genex reported a consolidated revenue of 11.7 billion won in the first quarter of this year, marking a 9.3% increase compared to the same period last year. The company's focus on high-value products and cost reduction strategies led to an operating profit of 1 billion won, a 25% increase year-on-year.



* This article has been translated by AI.